Zacks: Brokerages Expect Aevi Genomic Medicine Inc (GNMX) to Announce -$0.16 Earnings Per Share

Wall Street analysts expect Aevi Genomic Medicine Inc (NASDAQ:GNMX) to announce earnings per share (EPS) of ($0.16) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aevi Genomic Medicine’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). Aevi Genomic Medicine posted earnings of ($0.23) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 30.4%. The firm is expected to issue its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Aevi Genomic Medicine will report full-year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.59). For the next financial year, analysts anticipate that the firm will report earnings of ($0.92) per share, with EPS estimates ranging from ($1.27) to ($0.57). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Aevi Genomic Medicine.

Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01.

Separately, ValuEngine raised shares of Aevi Genomic Medicine from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd.

A number of large investors have recently made changes to their positions in the business. Wedbush Securities Inc. bought a new position in Aevi Genomic Medicine in the 2nd quarter valued at $233,000. JPMorgan Chase & Co. lifted its holdings in shares of Aevi Genomic Medicine by 4,715.1% during the 1st quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 99,018 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Aevi Genomic Medicine by 515.8% during the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 78,400 shares during the last quarter. 22.80% of the stock is owned by hedge funds and other institutional investors.

Aevi Genomic Medicine traded down $0.03, hitting $0.98, during trading hours on Tuesday, MarketBeat reports. The stock had a trading volume of 17,467 shares, compared to its average volume of 106,832. Aevi Genomic Medicine has a one year low of $0.83 and a one year high of $2.65.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Further Reading: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aevi Genomic Medicine (NASDAQ:GNMX)

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply